Abstract library

1312 results for "Carcinoid Hearth Disease".
#2260 Carcinoid Heart Failure in a Metastatic Duodenal Neuroendocrine Tumor: A Challenging Case Report.
Introduction: Carcinoid heart disease (CHD) is a potenzial fatal cardiac manifestation, characterized by fibrous endocardial thickening involving right-sided heart valves. In 70% of cases, CHD occurs in advanced small bowel NETs with carcinoid syndrome (CS). Serotonin seems to play a main role. Early recognition and surgical intervention may improve the outcome of patients.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: Dr Anna La Salvia
#104 Myocardial motion abnormalities in patients with carcinoid disease without overt carcinoid heart disease
Introduction: Cardiac abnormalities occur in 15-70% of patients with carcinoid disease, typified by fibrosis of the right-sided valves. Myocardial motion abnormalities in subjects without overt carcinoid heart disease have not been previously described. Tissue Doppler Imaging (TDI) allows quantative analysis of myocardial motion. We used this technique to investigate whether myocardial motion is reduced, suggesting fibrosis, in patients with carcinoid disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Christopher Wong
#2944 Soluble ST2 (sST2) Levels in the Management of Carcinoid Heart Disease in Patients with Neuroendocrine Cancer
Introduction: The identification of a sensitive biomarker to detect the presence and severity of carcinoid heart disease could allow more selective use of clinical and echocardiographic screening. ST2 is a protein belonging to the family of interleukin 1 receptors, present both in the isoform of transmembrane (ST2L) and in the soluble one (sST2). sST2 blocks the anti-inflammatory, anti-hypertrophic, and anti-fibrotic effects of cytokine IL-33 on the myocardium and recent studies have shown that sST2 levels increase in the blood of patients diagnosed with heart failure.
Conference: 17th Annual ENETS Conference (2020)
Category: Biomarkers
Presenting Author: Daniela Maria Cardinale
#105 A pilot study using biochemical markers to predict acrcinoid heart disease in patients with carcinoid disease
Introduction: Carcinoid heart disease (CHD) affects up to 15-70% of patients with carcinoid disease. Recent ENETS guidelines recommend regular echocardiographic assessment to screen for CHD. Chromogranin A (CgA) is a peptide widely used to monitor carcinoid disease progression. Neurokinin A is a tachykinin which may be a more sensitive measure of carcinoid disease progression and prognosis. N-terminal pro Brain Naturetic Peptide is used as a screening tool for heart failure and recent results suggest utility in the diagnosis of CHD.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Christopher Wong
#139 Association of carcinoid with noncarcinoid neoplasms
Introduction: Carcinoid tumors have a complex disease spectrum. Most have a benign clinical course, but some are aggressive, with invasive growth, metastasis and short survival. In carcinoid tumors, more than 20% are associated with noncarcinoid neoplasms. When the second tumor is a more malignant lesion, the prognosis usually is correlated more closely with the noncarcinoid malignant neoplasm.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Joao C Ribeiro
#1138 Staged Percutaneous Treatment of Severe Carcinoid Heart Disease by Transfemoral Pulmonary Valve Replacement and Novel Vena Cava Valve Implantation
Introduction: Carcinoid heart disease with severe valve destruction represents the major cause of high morbidity and mortality in patients with carcinoid syndrome.
Conference: 12th Annual ENETS Conference (2015)
Category: Clinical cases/reports
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Laule M, Baur A, Pape U F, ...
#261 Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures
Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks
Authors: Zacks J, Shafir M, Castillo J, Choi J, ...
#1272 Telotristat Etiprate Appears to Halt Carcinoid Heart Disease
Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.
Conference: 13th Annual ENETS conference (2016)
Category: Medical treatment - Others
Presenting Author: MD, FACC, FCCP Jerome Zacks
Authors: Zacks J, Lavine R, Ratner L, Warner R, ...
#1296 The Application of Octreotide in a SINET Patient with Carcinoid Syndrome, Carcinoid Heart Disease and Carcinoid Crisis: A Case Report
Introduction: In Chinese population, small intestinal neuroendocrine tumor (SINET) only accounts for 2.2% of gastroenteropancreatic NET, while carcinoid syndrome, carcinoid heart disease (CHD) and carcinoid crisis are rarer.
Conference: 13th Annual ENETS conference (2016)
Category: Clinical cases/reports
Presenting Author: Luohai Chen
Authors: Chen L, Zhang Y, Chen M, Chen J, ...
#2164 A Case of Carcinoid Induced Heart Disease
Introduction: Carcinoid Heart disease is a common disease with neuroendocrine malignancies that invade the liver due to the paraneoplastic effects of vasoactive substances such as 5-hydroxytryptamine, histamine and tachykinins released by malignant cells rather than any direct metastatic involvement of the heart.
Conference: 15th Annual ENETS conference (2018)
Category: Case reports
Presenting Author: doctor Suhel Ashraff
Close
Notice

Dear conference participant,

Thank you for participating in the ENETS Virtual Conference 2020!

You now have the opportunity to view the webcasts, abstracts and e-posters via My ENETS. Don't miss on any of the exciting talks and take your time to view the clinical and basic science abstract sessions.

If you require a certificate of attendance, please log into My ENETS and select “Annual Conferences” from the side menu, then click on “My registrations” and select your registration for 2020. Please choose "Certificate o.A." to receive your certificate of attendance.

A note on CME accreditation:

ENETS has been liaising with UEMS regarding CME accreditation for the virtual conference. At present, we do not have a definitive answer. We will keep you updated.

 

Wishing you all the best,

The entire ENETS team